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ABSTRACT Few promoters are active at high levels in all
cells. Of these, the majority encode structural RNAs tran-
scribed by RNA polymerases I or III and are not accessible for
the expression of proteins. An exception are the small nuclear
RNAs (snRNAs) transcribed by RNA polymerase II. Although
snRNA biosynthesis is unique and thought not to be compat-
ible with synthesis of functional mRNA, we have tested these
promoters for their ability to express functional mRNAs. We
have used the murine Ula and Ulb snRNA gene promoters to
express the Escherichia coli lacZ gene and the human a-globin
gene from either episomal or integrated templates by trans-
fection, or infection into a variety of mammalian cell types.
Equivalent expression of f3-galactosidase was obtained from
<250 nucleotides of 5'-flanking sequence containing the
complete promoter of either Ul snRNA gene or from the
750-nt cytomegalovirus promoter and enhancer regions. The
mRNA was accurately initiated at the Ul start site, efficiently
spliced and polyadenylylated, and localized to polyribosomes.
Recombinant adenovirus containing the Ulb-lacZ chimeric
gene transduced and expressed ,B-galactosidase efficiently in
human 293 cells and airway epithelial cells in culture. Viral
vectors containing Ul snRNA promoters may be an attractive
alternative to vectors containing viral promoters for persis-
tent high-level expression of therapeutic genes or proteins.
A prime requirement for successful gene therapy in many
clinical situations is the sustained high-level expression of the
therapeutic gene without any adverse effect on the recipient
(1-3). In most cases the expression of transgenes is shut off
when introduced through viral vectors either under the control
of a viral long terminal repeat or heterologous internal pro-
moters (4, 5). In at least one case, shut off correlated with
specific in vivo methylation of the viral/vector DNA (6). Using
a constitutive endogenous promoter, such as the dihydrofolate
reductase promoter, can lead to long lasting expression, albeit
at very low levels, suggesting that the choice of a suitable
cellular promoter-enhancer combination may be necessary for
long-term high level expression (4). The coupling of viral
promoter elements to cellular enhancers, or cellular promoters
to viral enhancers, has recently been tried as an alternative to
sustain high-level transgene expression. Constitutive expres-
sion has been obtained from recombinant retroviral vectors in
which the mouse muscle creatine kinase enhancer was linked
to the human cytomegalovirus (HCMV) promoter (7). Other
vectors have been constructed in which the HCMV enhancer
has been linked to the human ,B-actin gene promoter with
similar constitutive expression (8). While promising, the cur-
rent levels of expression obtained from these constructs and
the persistence of expression in vivo is still being evaluated.
For this reason, identification of high level constitutive
promoters that may resolve some of these concerns is still of
interest. RNA polymerase II transcribes a variety of genes,
including the spliced and polyadenylylated mRNAs, the non-
polyadenylylated histone mRNAs and many of the U series of
small nuclear RNAs (snRNAs). The U series of snRNA genes
are expressed at high rates in all growing cells, and there is
continued expression independent of the growth state of the
cells. Hence these genes are good candidates for cellular
promoters that may help cell-type independent expression.
Genes for snRNAs do not contain introns and have unique 3'
ends. In mammalian cells the formation of the 3' ends of the
snRNAs transcribed by RNA polymerase II requires that the
polymerase initiate from the snRNA promoter (9, 10). There
is a poorly conserved consensus sequence 3' to the end of the
primary transcript (11) which directs snRNA 3'-end forma-
tion. If a heterologous promoter replaces the snRNA pro-
moter, then the snRNA 3' end is not formed and transcription
continues past the normal termination site (9, 10). These
results suggest that a sequence within the snRNA promoter is
required for proper snRNA 3'-end formation and that 3'-end
formation occurs cotranscriptionally, probably by transcription
termination. Further studies with these sequences have sug-
gested that transcripts which initiate at snRNA promoters do
not form functional polyadenylylated mRNAs (12). It is likely
that the failure to drive polyadenylylated mRNA expression
from U snRNA promoters was at least partially due to
premature termination of transcripts carrying cryptic 3'-end
signals (12). We have previously shown that a snRNA pro-
moter will direct formation of functional histone 3' ends, and
that functional histone mRNA can be produced from chimeric
Ul-histone genes (13). Histone genes share some common
features with U snRNA genes in that they do not contain
introns and do not encode polyadenylylated RNAs.
Here we describe the expression of heterologous genes
containing introns and polyadenylylation signals from a U
snRNA promoter. We have successfully utilized promoter
elements of the murine Ul snRNA genes to provide high level
expression of Escherichia coli 13-galactosidase ((3-gal) and
human a-globin gene constructs upon transfection into mam-
malian cells. Messenger RNA synthesis is accurately initiated
from the Ul promoters and the transcripts are efficiently
spliced and polyadenylylated. In addition, we demonstrate that
the murine Ul promoter is capable of driving gene expression
from either episomal constructs or integrated sequences in a
variety of human cell types. Constructs containing the Ul
promoters express ,3-gal at levels comparable to that produced
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from the HCMV promoter and enhancer elements. Recom-
binant adenovirus containing the bacterial lacZ gene driven by
the Ulb promoter have been produced and shown to transduce
and express the lacZ gene efficiently in human 293 and CF
airway epithelial cells in culture. Due to the relatively small size
and high activity of the Ul promoter, gene cassettes containing
Ul promoters may be attractive alternatives to viral promoters for
the high level expression of heterologous genes and may be useful
for the expression of therapeutic proteins and gene therapy.
MATERIALS AND METHODS
Cell Culture. Human 293 cells were grown in complete
Dulbecco's modified Eagle's medium (GIBCO) supplemented
with 10% FCS. The cystic fibrosis airway epithelial cell line,
CFT-1, was obtained from Richard Boucher and maintained in
hormone-supplemented F-12 medium as described (14). Chi-
nese hamster ovary (CHO) cells were grown in McCoy's 5A
medium (GIBCO) containing 10% FCS.
Recombinant Plasmid and Viral Constructs. pnlacF en-
codes a modified E. coli ,B-gal that localizes to the nucleus and
has an intron and polyadenylylation signals from the mouse
protamine 1 structural gene. pCMVnlac was constructed to
verify the utility of pnlacF as a transcriptional fusion vector and
to serve as a positive control for the expression studies.
pCMVnlac contains the HCMV immediate early promoter
and enhancer region (XhoI/PstI) (-778 to +21) from pEXP22
(16, 17) inserted into the XbaI site of pnlacF. Plasmid
pMUlbnlac was constructed by inserting the 340 bp PvuII/
XbaI fragment, containing the murine Ulb promoter (-226 to
+5), of pU1+5 (13) into SmaI/XbaI cleaved pnlacF (15). The
plasmid pMUlanlac was constructed similarly by inserting a
394 bp fragment, containing sequences from -246 to +5 of the
murine Ula promoter (18) into the XbaI site of the pnlacF.
Since the first five nucleotides of Ula and Ulb transcripts are
identical, these two plasmids direct the synthesis of identical
RNAs. Plasmids pUlbcG and pUlbG contained the same mu-
rine Ulb promoter, the complete human a-globin cDNA or
genomic DNA sequence, and the mouse ,3-globin polyadenyl-
ylation signal added at the BglI site in the 3'-untranslated region
(19). Constructs containing these globin sequences driven by a
histone promoter have been previously described (19).
For the generation of recombinant adenovirus, the PstI
fragment containing the lacZ gene and MUlb promoter from
pMUlbnlac was cloned into a derivative of the pXCX2 plasmid
(20), pXCJL.1 (a gift from Frank Graham, University of
British Columbia, Vancouver, Canada), and cotransfected
with the XbaI/ClaI fragment of adenovirus 5 d1309 DNA into
293 cells using calcium phosphate-mediated DNA transfer
(21). Recombinant adenovirus plaques were isolated as de-
scribed (22) and tested for (3-gal expression after infection of
293 cells. A positive plaque was purified again and designated
AdMUInlac. The recombinant viral particles were grown and
purified as previously described (23) except that after double
CsCl banding the virus was extensively dialyzed against 10 mM
Tris/1 mM MgCl2, pH 7.4, containing 10% glycerol. The
purified virus was stored in aliquots at -20°C. The virus titer,
determined by absorbance at 260 nm and plaque assay, ranged
from 0.5-2.0 x 1011 plaque-forming units per ml.
Transfections. CHO cells were seeded at 1 x 104 cells/cm2
in 10-cm dishes. Two days later, the cells were washed twice
with serum-free growth media (Opti-MEM; GIBCO) and
transfected with plasmid DNA by lipofection (24). The DNA
(10 tLg) was diluted into 0.8-ml of Opti-MEM medium, and 200
,tg of Lipofectamine reagent (GIBCO/BRL) were mixed in
0.8 ml of Opti-MEM medium. The DNA and Lipofectamine
solutions were mixed, incubated at room temperature for 15
min, and added to the cells. After 18 h at 37°C, 12 ml of fresh
Opti-MEM medium were added. Eighteen hours later, the
cells were washed and processed to determine ,B-gal and
luciferase activities. Stable transfectants in CHO cells were
made by co-transfecting the U1-lacZ genes or the chimeric
Ulb globin construct with pSV2neo as previously described
(25, 26), except poly L-ornithine (27) was substituted for
Polybrene in the transfection medium.
Human CFT1 cells were seeded onto polylysine coated glass
chamber slides at '30% confluence density (LabTek). Two
days after seeding the cells were washed with fresh F-12 + 7x
medium and transfected with plasmid DNA (100 ng/cm2) by
lipofection. Transfection proceeded as described above except
that F-12 + 7x medium was used and the DNA-lipid mixture
was incubated with the cells for only 2 h prior to adding fresh
medium.
Histochemical Staining and Immunofluorescence. (3-gal
histochemistry in transfected cells was performed according to
Sanes et al. (28) with the following minor modifications.
Briefly, cultured cells were rinsed with PBS solution (pH 7.4)
and then fixed for 10 min at 5°C in 1.8% formaldehyde/0.2%
glutaraldehyde in PBS. The cells were then rinsed three times
with PBS and overlaid with a solution containing 1 mg/ml of
5-bromo-4-chloro-3-indolyl (-D-galactoside per ml, 5 mM potas-
sium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM
MgCl2 in PBS (pH 7.4). Incubation was at 37°C for 2-24 hr.
Human a-globin expression was evaluated by indirect im-
munofluorescence using a purified polyclonal IgG antibody
against human hemoglobin (Sigma). CHO cells stably express-
ing the Ulb/a-globin gene were grown on glass slides and fixed
in methanol:acetone (1:1) at -20°C for 10 min. After rehy-
drating in PBS containing 1.5 mM MgCl2, and washing with
wash buffer (20 mM Tris HCl, pH 7.6, 137 mM NaCl, 3 mM
KCl, 1.5 mM MgCl2, 5 mg/ml BSA, and 0.05% Tween 20) the
cells were incubated with anti-hemoglobin antibody (1:8) for
1 h at 37°C. Following another series of washes with wash
buffer the cells were incubated with fluorescein isothiocya-
nate-conjugated goat anti-rabbit IgG (Sigma; 1:160) that had
been purified by chromatography on protein-G Sepharose
(Pharmacia), for 1 h at 37°C, washed again, mounted in PBS
containing 80% glycerol and 0.2 M n-propyl gallate, and
examined by fluorescence microscopy.
Analysis of RNA. RNA extraction and S1 nuclease protec-
tion reactions were performed as described previously (29). In
some experiments CHO cells were fractionated into nuclear,
polyribosomal and cytosolic fractions as described (13). The
S1-resistant hybrids were denatured and the protected DNA
analyzed by gel electrophoresis on 7 M urea/6% polyacryl-
amide gels.
,8-gal Assays. Thirty-six hours posttransfection the cells were
harvested and lysed in Reporter lysis buffer (Promega). Co-
transfection with pGL2-Control vector (Promega) expressing
firefly luciferase was used as a control for transfection effi-
ciencies; expression from this plasmid was not affected by
either the pCMVnlac or pMUlnlac expression vectors. Each
assay was repeated at least three times independently, and each
experiment was repeated five times. The (3-gal assay was
performed by adding extract to an equal volume of 2x assay
buffer (Promega), which contained the substrate o-nitrophenyl
,B-D-galactopyranoside. Samples were incubated for 90 min,
the reactions were terminated, and the absorbance at 420 nm
was measured (30). Luciferase activity was determined from
the same extract using a luminometer (31).
RESULTS
The MUl snRNA Promoters Efficiently Drive Expression of
Heterologous Genes. snRNA transcripts do not contain introns
and are not polyadenylylated. The 3'-ends of these RNAs are
formed by a unique mechanism involving cotranscriptional
termination utilizing a sequence located 3' of the snRNA gene
(9-11). To determine whether mouse Ul snRNA promoters
could direct transcription of a linked heterologous gene, the
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MUlb or MUla promoter and 5 nucleotides (
sequence were cloned upstream of the E. coli ,B-ga
the pMUlanlac and pMUlbnlac genes and upst
human a-globin gene to give the pUlbG and pt
depicted in Fig. 1. As a first step in this stud
sequence analysis indicated that there were n
snRNA termination sites present in the lacZ or a
sequences. Expression from these constructs was
Si nuclease analysis of cytoplasmic RNA after
stable expression in CHO cells. To validate that ex
driven by the Ul promoter, it was important to s
transcripts initiated were at the proper start site z
derived from initiation at cryptic upstream promo
readthrough into the lacZ gene. A 191-nt fragmei
from the Earl site located in the lacZ gene (180 nt
snRNA start site) to the MscI site located 11 nt
start site in the Ula promoter, was cloned into p]
probe labeled at the 5' end of Earl site extending
polylinker was used for the Si nuclease prote
Transcripts initiating at the mouse Ul start site v
180-nt fragment from this probe. This probe
sensitive assay for the presence of incorrectly ini
since any transcripts which initiate anywhere moi
5' of the Ul start site will protect a 191-nt fragme
Transcripts from the pCMVnlac gene will prote
fragment from this probe, allowing quantitative c
expression from the CMV and Ul promoter (se(
When this probe was used to map transcripts
cells stably transfected with the MUlanlac gene,
protected fragment mapping to the Ul snRNA s
observed (Fig. 2A, lane 3). We included a marker
2A, lanes 2 and 7) which would correspond to
read-through transcripts. Thus we conclude tha
95% of the transcripts reading into the lacZ gene iI
the Ul promoter.
Transcripts from the Ul Promoter Are Spliced,









MU1b Human a-Globin 13G
pU1bcG rT
MUlb Human a-Globin 13G
FIG. 1. Structure of plasmid vectors containing
a-globin genes. Plasmids pMUlanlac, pMUlbnlac and F
different promoters to express lacZ: the murine Ula (2
(226 nt) snRNA promoter or the HCMV immediate e
(HCMV, 750 nt). Plasmid pnlacF contains no eukary
elements and was used as a negative control in th
experiments. Plasmid pUlbG and pUlbcG contaii
genomic a-globin gene or cDNA respectively driven by ti
promoter. The open boxes represent the coding region
tive genes. The thin lines indicate the 5'- and 3'-un
quences. The arrow shows the start of transcription for
mPl, murine protamine-1 gene intron and polyadenylyh
simian virus 40 nuclear localization signal; f3G, mu
polyadenylylation signal; A, Earl; *, EcoRI; 0, NcoI; 4
0, MscI.
of Ul RNA the transcripts from the Ul promoter were processed like
1 gene to give other mRNAs, we determined whether the transcripts were
tream of the spliced and polyadenylylated. The intron is located within the
JlbcG genes 3'-untranslated region of the MUlb-lacz gene, and therefore
Iy, computer nuclease protection experiments were performed using a
Lo consensus 3'-labeled probe that would detect spliced and unspliced
e-globin gene transcripts. A correctly spliced lacZ transcript would be ex-
measured by pected to protect a 190-nt fragment of this probe (Fig. 2B).
transient or Total RNA from transfected cells was fractionated into
ipression was polyA+ and polyA- RNAs by chromatography on oligo(dT)-
,how that the cellulose and analyzed by Si nuclease mapping. All of the
and were not MUlb-lacZ RNA was polyadenylylated and the major pro-
tters allowing tected fragment mapped to the 5' boundary of the mouse
nt, extending protamine 1 intron as expected, indicating that the transcripts
from the Ul were also correctly spliced (Fig. 2B, lane 2). Similar amounts
5' of the Ul of spliced RNAs were formed from the CMV-lacZ and MUlb-
BS. A 271-nt lacZ genes (not shown).
to end of the To show that the transcripts were correctly localized within
ction assays. the cell, we fractionated the CHO cells stably transfected with
vill protect a the pMUlanlac gene into nuclear, polyribosomal, and cyto-
provides a solic fractions. These fractions were assayed for histone
tiated RNAs mRNA, which is predominantly present on polyribosomes, and
re than 11 nt for the MUlanlac transcripts. The subcellular distribution of
znt (Fig. 2A). the MUlanlac transcripts (Fig. 2A, lanes 4-6) and the histone
ct an 176-nt H3 mRNA (Fig. 2A, lanes 9-11) were identical indicating that
Dmparison of the transcripts from the Ul promoter were localized to polyri-
e Fig. 3B). bosomes as efficiently as histone mRNAs.
s from CHO p8-gal Expression from the MUlb Promoter Is Equivalent to
only a single That from the HCMV Promoter. We determined the level of
;tart site was protein and RNA produced from the MUl promoters by
(191 nt, Fig. comparing 13-gal activity from the Ulb promoter to that from
any possible the HCMV sequences. The HCMV immediate early enhanc-
Lt more than er/element is considered very strong and has been used
nitiated from extensively to drive expression of heterologous genes. Plasmids
pMUlbnlac and pCMVnlac were transiently transfected into
Polyadenyl- CHO cells and the relative 13-gal activity was determined in cell
onstrate that extracts. The pGL2-Control vector encoding firefly luciferase
was transfected and assayed in the same cell extracts to
monitor transfection efficiency. We observed essentially iden-
tical 13-gal activity from both the HCMV and MUlb promoters
mP1 (Fig. 3A). In contrast, plasmid pnlacF, which lacks eukaryotic
regulatory sequences upstream of the lacZ gene, did not direct
synthesis of 13-gal above background levels. These data dem-
onstrate that the murine snRNA Ulb promoter is capable of
mP1 driving high-level expression of linked heterologous genes in a
transient assay.
T g The steady-state level of mRNA from the MUlanlac, the
_ L1 MUlbnlac and the CMVnlac genes was measured in stablymP1 transfected cell lines using the 5' S1 nuclease assay described
above. We analyzed pools of stably transfected cells. This
transfection protocol gives reproducible levels of expression
since the results are averaged over at least 50 independent
transfectants (26). These cell lines expressed similar amounts
of 13-gal as judged by the staining of the cells as well as by direct
measurement of enzyme activity in cell extracts (not shown).
The MUlanlac and MUlbnlac genes encode identical tran-
the 13-gal or scripts and hence give the same protected product, while the
)CMVnlac use CMVnlac transcripts differ 4 nt from the start site, resulting in
!46 nt) or Ulb a protected fragment that is 4 nt shorter. Equal amounts of
arly promoter total cell RNA was analyzed. The intensity of the protected
rotic promoter fragments was similar in all three cell lines, indicating that the
e transfection Ul promoters were as active as the CMV promoter (Fig. 3B,
n the human lanes 2-4), both in transient and stable transfections. The stably
he murine Ulb transfected pools of cells gave similar results when they were
of the respec- stained histochemically for 13-gal expression (data not shown).
each of genes. Expression of Human oi-Globin Genes from the Ulb Pro-
tion sinnal: n, moter. To demonstrate that the Ulb snRNA promoter can
rine ,B-globin direct expression of an authentic cellular gene and to deter-
*, BstEII; and mine whether the transcripts could be efficiently spliced, the
mouse Ulb promoter was fused to the 5'-untranslated region
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FIG. 2. Mapping of the transcripts from the U1-lacZ genes. (A) 50 jig of total cell RNA (T, lanes 3 and 8) or RNA prepared from nuclei (N,
lanes 4 and 9), polyribosomes (P, lanes 5 and 10) or cytosol (S, lanes 6 and 11) of CHO cells stably transfected with the pMUlanlac construct was
mapped using a Si nuclease protection assay. The probes are diagrammed below the figure. The line below the probes represents the size of the
expected protected fragments. The probe for the 5' pMUlanlac assay was a fragment containing 11 nt of 5'-flanking sequence and 180 nt from
the Ul start site in the pMUlanlac gene cloned in pBS (lanes 3-11). The 271-nt fragment containing pBS sequences fused to the MUlanlac sequence
was labeled at the 5' end of the EarI site. Any transcripts initiating at the Ula start site will protect a 180-nt fragment, while transcripts initiating
upstream of the Ula start site will protect a 191-nt fragment. The marker in lane 1 is pUC18 digested with HpaII. The marker in lane 2 and 7 is
pMUlanlac gene labeled at the Earl site, and then digested with MscI (see diagram below the figure). The resulting 191-nt fragment (lanes 2 and
7) is the fragment that would be protected by any read-through transcripts. The protected fragment, U15', maps to the Ul start site. P is residual
undigested probe. The same RNA samples were mapped using the histone H3-614 gene labeled at the Sall site as a probe (lanes 8-11). This probe
protects a 240-nt fragment (H3) from the hamster histone H3 mRNAs. (B) The 3' end of the transcripts was mapped using the MUlbnlac gene
labeled at the 3' end of the EcoRI site as probe. The RNA was fractionated into polyA+ (lane 2) and polyA- RNA (lane 3) by chromatography
on oligo(dT)-cellulose. Below the figure is a diagram of the Si nuclease assay. The line below the probe diagram represents the size of the expected
protected fragment. The protected fragment, SPL, maps to the 5' splice junction in the pMUlbnlac construct. Lane 1, analysis of 10 jig of yeast
tRNA; lane 2, analysis of 1.0 jig of polyA+ RNA; and lane 3, analysis of 30 ,ug of polyA- RNA.
of the human ca-globin gene. Two cassettes were characterized,
containing either cDNA (pUlbcG), or genomic globin
(pUlbG) sequences (Fig. 1), using probes derived from the
pUlbcG gene. These constructs were introduced into CHO
cells and analyzed, either transiently, or following selection of
stable transformants, by Si nuclease assays for correct 5'- and
3'-end formation. The 5' end of the transcripts from the two
genes was mapped using the pUlbcG gene labeled in the third
exon as a probe. A single fragment of 360 nt was observed from
both RNAs corresponding to the expected 5' end of the Ulb
RNA (Fig. 4A, lanes 2 and 3). This probe, which ends only 22
nt from the start of the third exon, will only protect spliced
transcripts, and hence the single protected fragment suggests
that all the transcripts were spliced. There was identical
expression of the globin gene regardless of whether introns
were present (Fig. 4A, lanes 2 and 3).
The 3' end of the transcripts from CHO cells stably trans-
fected with pUlbG gene were mapped using the pUlbcG
probe labeled at the NcoI site located at the translation
initiation codon. There is a single protected fragment of 590
nt (Fig. 4B, lane 2 and 3) that maps to the expected polyade-
nylylation site from the intron-containing pUlbG gene con-
struct. If any unspliced transcripts were present in significant
amounts, this 3' probe would protect a 93-nt fragment mapping
to the 5' splice junction in the first intron (19). We did not
detect any of the 93-nt fragment supporting the conclusion that
these transcripts have all been spliced (data not shown).
Identical results were obtained with RNAs from transiently
and stably transfected cells (data not shown).
Expression of human a-globin protein was also determined
in the stably transfected CHO cells. Cells stably transfected
with the pUlbG construct and selected with G418 were grown
without G418 for 4-6 weeks and the expression of a-globin
determined by immunofluorescence staining of the cells. All of
the cells in the culture expressed a-globin even after extensive
growth in the absence of selection (Fig. SF). Thus the MUlb
promoter is capable of stably and efficiently expressing an
authentic mammalian gene in cultured cells.
MUlb-Driven ,3-gal Expression in Human Airway Epithe-
lial Cells After Liposome or Viral Vector Transduction. To
determine if MUl-linked genes could be used to program
recombinant gene expression in a therapeutically relevant cell
type, plasmid pMUlbnlac was transfected into human CFT-1
airway epithelial cells using liposomes (14). The cells were
examined histochemically for ,3-gal gene expression 36 h
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pCMVnlac pMUl bniac pnlacF
FIG. 3. Comparison of pMUlnlac and pCMVnlac expression in
CHO cells. (A) Subconfluent monolayers of CHO cells were trans-
fected with plasmid DNA in conjunction with pGL2-control vector and
harvested at 48 h. 13-gal activity was determined relative to luciferase
activity in cell lysates and is plotted as the average of triplicate
determinations from five transfections ± SEM. (B) Fifty micrograms
ofRNA was prepared from cells stably transfected with the pCMVnlac
(lane 2), pMUlbnlac (lane 3), or pMUlanlac (lane 4) genes and the
amount of the transcripts was determined using the 5' Si nuclease
assay described in Fig. 2A. Lane 1 is the pMUlanlac gene labeled at
the Earl site, and then digested with MscI as in Fig. 2A. The protected
fragment, U15', maps to the Ul start site of the MUlanlac and
MUlbnlac transcripts, and to point of divergence at the 5' end of the
lacZ gene in the pCMVnlac transcripts. P, residual undigested probe.
observed in approximately 2-5% of the transfected cells
regardless of the promoter being used (Fig. 5 B and C). In
contrast, none of the control cells that received the pnlacF
plasmid demonstrated detectable ,3-gal activity (Fig. 5A).
To determine if MUl-linked transgenes could function in













FIG. 4. Mapping transcripts from the Ul-human
(A) Total cellular RNA (30 ,ug) prepared from CHO e
transfected with the UlbG construct (lane 2), the U]
(lane 3), using the UlbcG construct labeled at the Bs
third exon as a probe. The line below the probe diagrair
expected protected fragment (360 nt), mapping to the L
site (U15'). Lane 1 contains pUC18 DNA digested M
Total cellular RNA from CHO cells stably transfected M
(30 jLg, lane 2; 60 ,ug, lane 3) was analyzed by S1 nuc
using the UlbcG construct labeled at the NcoI site as a
below the probe diagram represents the expected prote
Lane 1 is analysis of 30 ,ig of yeast tRNA. The 665-nt f
each of these lanes represents undigested probe. The 5'
fragment (GA+) in lanes 2 and 3 maps the spliced a-,
the polyadenylylation site. Lane 4 is pUC18 digested
diagram of the assays is shown below the figure.
FIG. 5. Expression of MUI-linked transgenes. Histochemical ex-
pression of 13-gal activity in CFT-1 cells in vitro; CFT-1 cells were
transfected with either pnlacF (A) or pCMVnlac (B), or pMUlbnlac
(C), or infected with AdMUlnlac (D) and stained for 13-gal activity.
Human a-globin expression was determined by indirect immunostain-
ing using primary anti-hemoglobin rabbit antiserum and fluorescein
isothiocyanate-labeled goat anti-rabbit antibody; differential interfer-
ence contrast (E) and fluorescence (F).
defective adenovirus that carried the MUl-driven lacZ gene.
This virus, designated AdMUlnlac, was used at an multiplicity
of infection of 1 to infect CFT-1 cells grown on glass slides.
Histological examination of the CFT-1 cells following recom-
binant adenovirus infection demonstrated intense 13-gal gene
expression in >30% of the cells (Fig. SD).
DISCUSSION
a rep;ication- Transfection and Expression. We have shown that the
MUlb promoter and enhancer region (-226 to +5) is capable
of driving transcription of the lacz and human a-globin genes
in transfected human CFT1 and CHO cells, as well as human
HeLa, A549, and 293 cells (data not shown). The mRNAs
derived from the MUl promoters were initiated at the first
nucleotide of Ul snRNA and the transcripts were spliced and
polyadenylylated correctly. Further analysis indicated that
G A+ transcripts were expressed as efficiently from the MUl pro-
moters as from the HCMV promoter and enhancer. The high
489 level expression characterized with these promoters was func-
tional from both episomal and stably integrated sequences.
404 The failure of previous attempts to drive expression of the
4 bacterial chloramphenicol acetyltransferase gene from the
human Ul snRNA promoter may have been due to the
presence of cryptic snRNA termination sites within the gene
(12). In vertebrate systems, the sequences required for tran-
o- (665 nts) scription termination have been shown to lie entirely 3' of the
native Ul snRNA gene in a loosely conserved sequence, the 3'
G A box (11, 32). Although termination of transcription at this site
(S90 nts) is efficient, it functions only when the gene is transcribed from
an snRNA promoter (9, 10). Since the sequence is quite
cells transiently variable, cryptic termination sites may appear frequently in the
lbcG construct coding and intron sequences of structural genes (11). We have
,tE11 site in the recently shown that the 3'-termination element functions best
i represents the when it resides within 250 nt of the promoter, and only weakly
Jl snRNA start at distances greater than 400 nt from the promoter (L.R. and
vith HpaII. (B) W.F.M., unpublished data). Therefore, to form a full-length
vith UlbG gene transcript from the MUl promoter it may only be necessary
clease mapping that there be no cryptic snRNA termination sites present
probe. The line within the first 300 to 400 nt of the transcript. Computer
acted fragment. analysis indicated that the lacZ and a-globin genes do not
ragment (P) in contain any consensus snRNA termination sequences. The
globin RNA to fact that no sequences matching the Ul snRNA 3'-termination
with HpaII. A element were found within these genes may have been essential







1 2 3 4





















Proc. Natl. Acad. Sci. USA 93 (1996) 8857
Implications for Gene Therapy. A principal requirement for
successful gene therapy in many situations is long term high
level expression of the foreign gene. This has proven to be
difficult, and to date in vivo long-term expression other than
with immortalized cell lines has been attained only with limited
success. Although the problem of short duration of expression
in vivo can be attributed to a number of different factors, the
choice of promoter used to control the expression of the
transgene is one of the key players determining persistence (4,
7). This concern has forced many investigators to search for
other alternatives besides viral promoters. Tissue-specific pro-
moters, or combination of viral enhancers and cellular con-
stitutive promoters, have been the likely choices. We turned
our attention to the snRNA genes because they are constitu-
tively active at high levels in all cells. It is possible that the
snRNA promoters will not fall victim to the same mechanisms
that often down-regulate expression from exogenous viral
promoters. This makes these promoters attractive candidates
for driving the sustained high-level expression of therapeutic
transgenes in a number of different vectors. In addition the
small size of the Ul snRNA promoters may make them
particularly useful in viral vectors that often have severe size
constraints.
Our results indicate that the murine Ul promoters can be
used to drive the high-level expression of linked genes from
both episomal or integrated templates. We also demonstrate
efficient expression after liposome or viral delivery suggesting
that this promoter may prove an attractive alternative to
promoters currently being used to drive transgene expression.
In addition to the murine Ul promoters, we have observed
similar activities with the human Ul gene promoter in driving
expression of the bacterial lacZ gene (M.S. and J.S.B., unpub-
lished work). Furthermore, recombinant viral vectors contain-
ing murine Ulb-driven genes have recently been shown to
transduce and express in primary cells and tissues (University
of North Carolina Gene Therapy Center, unpublished results).
Although, the persistence of snRNA-linked transgene expres-
sion in vivo has yet to be determined, data provided in this
study suggest that critical in vivo analysis of these promoters is
warranted and may be facilitated by the construction of our
MUlb recombinant lacZ adenovirus.
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